Lilly Chair and CEO Dave Ricks speaks during a press conference for Eli Lilly and Company in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | ReutersEli Lilly and Nvidia are partnering to build what they call the pharmaceutical industry’s “most powerful” supercomputer and so-called AI factory to help accelerate drug discovery and development across the sector, the companies announced Tuesday. It’s the latest stride by Nvidia and the pharmaceutical industry to harness AI to help shorten the time it takes to bring cures to patients, while reducing costs at every stage of drug discovery and development. The process typically takes about 10 years on average from dosing the first human with a drug to its launch on the market, said Diogo Rau, Eli Lilly’s chief information and digital officer, in an interview. Eli Lilly expects to complete the buildout of the supercomputer and AI factory in December. They will go online in January. But the new tools likely won’t yield significant returns for the company’s business and that of any other drugmaker until the end of the decade. “The things that we’re talking about discovering with this kind of power that we have right now, we’re really going to see those benefits in 2030,” Rau said. The industry’s efforts to use AI to bring medicines to people faster are still in the early stages. There are no drugs on the market designed using AI, but progress is evident in the number of AI-discovered drugs entering clinical trials, recent AI-focused investments and partnerships among drugmakers.Eli Lilly will own and operate the supercomputer, which will be powered by more than 1,000 Blackwell Ultra GPUs – a newer family of chips from Nvidia – connected on a unified, high-speed network. The supercomputer will power the AI factory, a specialized computing infrastructure that will develop, train and deploy AI models at scale for drug discovery and development.The supercomputer “is really a novel scientific instrument. It’s like an enormous microscope for biologists,” said Eli Lilly’s Chief AI Officer Thomas Fuchs. “It really allows us to do things we couldn’t do before at that enormous scale. Scientists will be able to train AI models on millions of experiments to test potential medicines, “dramatically expanding the scope and sophistication” of drug discovery, according to a release from Eli Lilly. While finding new drugs isn’t the only focus of the new tools, it is “where the big opportunity is,” said Rau.”We’re hopeful that we’ll be able to discover new molecules that we never would have with humans alone,” he said. Several AI models will be available on Lilly TuneLab, an AI and machine learning platform that allows biotech companies to access drug discovery models that Eli Lilly has trained on years of its proprietary research. That data is worth $1 billion.Eli Lilly launched that platform in September as a way to expand access to drug discovery tools across the sector. “It’s really powerful to be able to give that extra starting point to these startups …
